XHKG
6699
Market cap1.82bUSD
Oct 09, Last price
82.30HKD
1D
-1.08%
1Q
12.13%
IPO
-78.34%
Name
Angelalign Technology Inc
Chart & performance
P/E
60.52
P/S
4.65
EPS
1.16
Div yield, %
1.01%
Shrs. gr., 5y
0.38%
Rev. gr., 5y
26.00%
Revenues
2.59b
+32.16%
Net income
199m
+125.21%
CFO
712m
+4,109.18%
Dividend
Sep 10, 20264.57 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner Pro and Angel Aligner Classic, are bespoke, removable clear aligners designed to gradually guide a patient's teeth into proper alignment over time. Beyond aligner development, the company also operates dental clinics that provide a variety of services, including orthodontics and cosmetic dentistry, and distributes intraoral scanners. Their extensive portfolio of clear aligner brands features Angelalign, Angelalign Pro, Angelalign Kid, and COMFOS. The firm was founded in 2003 and maintains its principal offices in Shanghai, China.
Key people
Dai Feng
Non-Executive Chairman of the Board · since 2018
Richard Hirschland
Senior Vice President, Global Chief Commercial Officer · since 2024
Lingbo Zhu
Senior Vice President, Board Secretary, Joint Company Secretary · since 2020
Jiezhang Hu
Chief Executive Officer, Chief Technology Officer, Executive Director · since 2023
Chief Financial Officer, Executive Director · since 2023
Kun Huang
President - Global Business, Executive Director · since 2023
Xin Song
Chief Operating Officer, Executive Director · since 2023
Joint Company Secretary · since 2021
Leong Yin Lee
Company Secretary · since 2025
Independent Non-Executive Director · since 2021
Zi Shi
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||